Literature DB >> 19047225

Randomized pilot study comparing oral ibuprofen with intravenous ibuprofen in very low birth weight infants with patent ductus arteriosus.

Ahmed Cherif1, Naima Khrouf, Sami Jabnoun, Chahnez Mokrani, Moez Ben Amara, Nedia Guellouze, Samia Kacem.   

Abstract

BACKGROUND: We conducted a prospective, randomized, single-masked pilot study with the principal aim of comparing efficacy and tolerance between oral and intravenous ibuprofen in early closure of patent ductus arteriosus in very low birth weight infants. The possibility of ductal closure with only 1 or 2 doses of treatment was a secondary objective.
MATERIAL AND METHODS: Sixty-four very low birth weight patients with echocardiographically confirmed patent ductus arteriosus and respiratory distress were studied. The patients were randomly assigned to receive either oral (group O, n=32) or intravenous (group I, n=32) ibuprofen starting on the third day of life. After the first dose of treatment in both groups, echocardiographic evaluation was performed to determine the need for a second or third dose. The rate of ductal closure, adverse effects, complications, and the patient's clinical course were recorded.
RESULTS: In each group, 24 (75%) patients were born after 28 weeks' gestation. The rate of ductal closure tended to increase in group O (84.3% vs 62.5%). Closure of the ductus was obtained after 1 or 2 doses of treatment in 19 (70.3%) of 27 patients in group O and 14 (70%) of 20 patients in group I. The adverse effects were increased in group I (31.2% vs 9.3%). There were no significant differences with respect to complications during the stay. Adverse effects were significantly fewer when closure was achieved after an incomplete course of treatment (23.1% vs 76.9%).
CONCLUSIONS: In very low birth weight infants, the rate of early ductal closure with oral ibuprofen is at least as good as with the intravenous route. Ductal closure may be obtained with an incomplete course of ibuprofen. Oral ibuprofen is associated with fewer adverse effects. However, a larger sample is needed for more definitive conclusions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19047225     DOI: 10.1542/peds.2008-1780

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  18 in total

1.  Comparison of posterolateral thoracotomy and video-assisted thoracoscopic clipping for the treatment of patent ductus arteriosus in neonates and infants.

Authors:  Haiyu Chen; Guoxing Weng; Zhiqun Chen; Huan Wang; Qi Xie; Jiayin Bao; Rongdong Xiao
Journal:  Pediatr Cardiol       Date:  2010-12-25       Impact factor: 1.655

2.  Ibuprofen potentiates the in vivo antifungal activity of fluconazole against Candida albicans murine infection.

Authors:  Sofia Costa-de-Oliveira; Isabel M Miranda; Ana Silva-Dias; Ana P Silva; Acácio G Rodrigues; Cidália Pina-Vaz
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

3.  Patent ductus arteriosus: indomethacin, Ibuprofen, surgery, or no treatment at all?

Authors:  Peter Gal
Journal:  J Pediatr Pharmacol Ther       Date:  2009-01

Review 4.  Evidence-based use of indomethacin and ibuprofen in the neonatal intensive care unit.

Authors:  Palmer G Johnston; Maria Gillam-Krakauer; M Paige Fuller; Jeff Reese
Journal:  Clin Perinatol       Date:  2012-01-13       Impact factor: 3.430

Review 5.  Oral medications regarding their safety and efficacy in the management of patent ductus arteriosus.

Authors:  Mehmet Yekta Oncel; Omer Erdeve
Journal:  World J Clin Pediatr       Date:  2016-02-08

6.  Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial.

Authors:  Sanju Yadav; Sheetal Agarwal; Arti Maria; Ajay Dudeja; N K Dubey; Puneet Anand; Dinesh Kumar Yadav
Journal:  Pediatr Cardiol       Date:  2014-01-17       Impact factor: 1.655

Review 7.  Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration.

Authors:  Sindhu Sivanandan; Ramesh Agarwal
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

Review 8.  Patent ductus arteriosus in preterm infant: Basic pathology and when to treat.

Authors:  Abdulrahman M H Al Nemri
Journal:  Sudan J Paediatr       Date:  2014

Review 9.  Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis.

Authors:  Souvik Mitra; Ivan D Florez; Maria E Tamayo; Lawrence Mbuagbaw; Thuva Vanniyasingam; Areti Angeliki Veroniki; Adriana M Zea; Yuan Zhang; Behnam Sadeghirad; Lehana Thabane
Journal:  JAMA       Date:  2018-03-27       Impact factor: 56.272

10.  Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.

Authors:  Arne Ohlsson; Rajneesh Walia; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2020-02-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.